---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-008977"
form_type: "8-K"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T14:48:19.833354+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biostage Q1 net loss widens to $2.2M; settles lawsuit, raises $5.1M placement

## Summary
- Q1 net loss of $2.2M ($0.20 per share) vs $0.9M loss ($0.09) in Q1 2021; G&A up $1.4M on legal costs.
- Raised $5.1M via private placement on May 12, 2022 to fund clinical development of BEI.
- Settled wrongful death lawsuit on April 27, 2022; total estimated costs $6.0M, $5.5M unpaid; HBIO to pay $4.0M.
- Cash on hand $0.7M at March 31, 2022; after placement, cash expected to fund operations through Q1 2023.

## SEC filing metadata
- accession: 0001558370-22-008977
- form_type: 8-K
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000155837022008977/0001558370-22-008977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000155837022008977/tmb-20220516x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-008977
- JSON: https://secwatch.observer/filing/0001558370-22-008977.json
- Plain text: https://secwatch.observer/filing/0001558370-22-008977.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.